Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Journal article

Open access

Peer reviewed

Marilyn K Glassberg, Steven D Nathan, Chin-Yu Lin, Elizabeth A Morgenthien, John L Stauffer, Willis Chou and Paul W Noble

Advances in therapy, Vol.36(10), pp.2927-2929

2019-09-09

PMCID: PMC6822818

PMID: 31502216

Abstract

In the Original Publication the colors of Figure 2 have been switched. The correct figures are given below.

url

https://doi.org/10.1007/s12325-019-01082-6View

Published (Version of record) Open

25 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.208 Vasculitis & Autoimmune Disorders; 1.208.1262 Idiopathic Pulmonary Fibrosis
Web Of Science research areas: Medicine, Research & Experimental; Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Creators: Marilyn K Glassberg - University of Miami Health System, Miami, FL, USA. MGlassbe@med.miami.edu
Steven D Nathan - Inova Fairfax Hospital, Falls Church, VA, USA
Chin-Yu Lin - Genentech, Inc., South San Francisco, CA, USA
Elizabeth A Morgenthien - Genentech, Inc., South San Francisco, CA, USA
John L Stauffer - Genentech, Inc., South San Francisco, CA, USA
Willis Chou - FibroGen, San Francisco, CA, USA
Paul W Noble - Cedars-Sinai Medical Center, Los Angeles, CA, USA
Publication Details: Advances in therapy, Vol.36(10), pp.2927-2929
Language: English
Resource Type: Journal article
PMID: 31502216
PMCID: PMC6822818
Record Identifier: 991031614607102976